Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambrosia trifida pollen is a sterile allergenic extract derived from the pollen of the giant ragweed plant. It is classified as a biologic and is used for both the diagnosis and treatment of allergies. For diagnosis, it is administered via percutaneous or intradermal skin tests to confirm sensitivity in patients with a clinical history of ragweed allergy. [4] For treatment, it is used as a form of immunotherapy, administered subcutaneously to reduce the allergic symptoms caused by ragweed pollen, such as allergic rhinitis (hay fever). [3, 4] The mechanism of action involves desensitization, where repeated administration of the extract modulates the patient's immune response to the ragweed allergens. This process is thought to involve a shift in T-cell responses and the production of blocking antibodies, which reduces the severity of the IgE-mediated allergic reaction upon environmental exposure to the pollen. [4] It is marketed under a Biologic License Application (BLA) and is available from several manufacturers, including Greer Laboratories (Stallergenes Greer) and ALK-Abelló, Inc. [3, 4, 14]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ambrosia trifida pollen.